Stockscreener 앱 받기
4.27
0.70%
-0.03
Ernexa Therapeutics Inc 주식(ERNA)의 최신 뉴스
ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results - Stocktwits
Ernexa appoints David Polinsky to board ahead of IND filing - Investing.com
Ernexa Therapeutics Announces Appointment of David Polinsky to Board of Directors - marketscreener.com
Ernexa Therapeutics Inc expected to post a loss of $3.84 a shareEarnings Preview - TradingView
Ernexa Therapeutics (NASDAQ: ERNA) details $9.5M loss and cash strategy - Stock Titan
Price to sales forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Ernexa Therapeutics Inc. Revenue Breakdown – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics (ERNA) Drops Nearly 5% as Bearish Pressure Builds Near Key SupportMarket Profile - dars.gov.et
Ernexa Therapeutics Inc. Revenue Breakdown – BOATS:ERNAW - TradingView
Ernexa Therapeutics Inc. (ERNA) stock price, news, quote and history - Yahoo Finance UK
Ernexa Therapeutics Inc. (ERNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ernexa Therapeutics advances ERNA-101, a cell t... - Pluang
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 - GlobeNewswire
Tumors cleared in about two-thirds of animals in ERNA-101 study - Stock Titan
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies - Yahoo Finance
Ernexa's Innovative Approach to Cancer Treatment - Intellectia AI
Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy - Sahm
ERNA Stock Whipsaws As Ernexa Maps Path To First Human Trial - StocksToTrade
ERNA stock jumps as investors appear to refocus on ERNA-101 clinical milestones - Quiver Quantitative
ERNA Stock Pops As Ernexa Flags Progress Toward First Trials - StocksToTrade
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA) - Yahoo Finance
ERNA Stock Draws Trader Attention As Biotech Maps 2026–2027 Trial Roadmap - timothysykes.com
Wednesday's pre-market session: top gainers and losers - ChartMill
Ernexa's ERNA-101 combo clears tumors and boosts survival in ovarian cancer preclinical study. - Pluang
Ernexa reports positive preclinical data for cancer therapy By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Ernexa Therapeutics Reports Independent Preclinical Validation of ERNA-101 Combination Therapy Ahead of Planned IND Submission - Quiver Quantitative
Ernexa Therapeutics stock surges 30% on preclinical data By Investing.com - Investing.com Canada
Ernexa Therapeutics Receives Independent Validation of - GlobeNewswire
Ernexa plans IND filing for ovarian cancer therapy ERNA-101 By Investing.com - Investing.com Canada
Ernexa Therapeutics plans first-in-human trial of ERNA-101 for ovarian cancer in late 2026 - Pluang
Preclinical ovarian models: Ernexa's ERNA-101 cleared tumors with PD-1 blockade - Stock Titan
Ernexa Therapeutics Inc. Q3 2023 Earnings: Pre-Revenue Biotech Reports Net Loss Amid Pipeline ProgressAnalyst Drop Coverage - po-news-eg.net
Eterna Therapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
Eterna Therapeutics Updates Investor Presentation, Highlights Web Disclosures - TipRanks
Updated July 2026 investor presentation from Ernexa Therapeutics (NASDAQ: ERNA) - Stock Titan
Ernexa Therapeutics (ERNA) investors back directors, auditor and 2026 equity plan - Stock Titan
ERNA Q3 2023 Earnings: Reported Loss per Share of -$1.03, Stock Rises $1.37Revenue Growth Outlook - dars.gov.et
ERNA stock shoots up 140% in a month: Here's what you should know - MSN
Ernexa Therapeutics (ERNA) Posts Modest Gain as Stock Holds Above Key SupportInsider Selling Alerts - dars.gov.et
Ernexa Therapeutics Warrants (ERNAW) Hold Steady at $0.06 – A Waiting Game for CatalystsUnusual Call Volume - dars.gov.et
Price to sales forward of Ernexa Therapeutics Inc. – BOATS:ERNAW - TradingView
Price to earnings forward of Ernexa Therapeutics Inc. – BOATS:ERNAW - TradingView
Bio-Techne Soars Over 20% on Merck Acquisition News - Intellectia AI
Eterna Therapeutics announces finance leadership transition and search - TipRanks
Sandra Gurrola to Resign as Ernexa's Senior VP of Finance, Effective July 3, 2026 - TradingView
Ernexa Therapeutics (ERNA) finance SVP resigns, will aid transition - Stock Titan
Ernexa Therapeutics (ERNA) Slides 12% as Selling Pressure IntensifiesBreak of Structure - dars.gov.et
Ernexa Therapeutics Surges 20.6%: Momentum Builds for ERNA Stock After BreakoutVolume Nodes - dars.gov.et
ERNA Forecast — Price Target — Prediction for 2027 - TradingView
Ernexa Therapeutics Launches CEO Corner Platform to Highlight Scientific Strategy and Mission - Quiver Quantitative
Ernexa uses video to explain its cell-therapy strategy and patient mission - Stock Titan
0.52%
0.07%
자본화:
|
볼륨(24시간):